Myasthenia gravis: diagnostic, prognostic, and treatment response markers

Myasthenia gravis: diagnostic, prognostic, and treatment response markers - Myasthenie-Kohorte

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024428

Enrollment

1600

Registered

2021-02-10

Start date

2011-03-09

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G70

Interventions

Group 1: myasthenia gravis Group 2: healthy controls Group 3: other autoimmune diseases

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria Myasthenia patients: - Confirmed diagnosis of myasthenia gravis. - Men and women - Ability to give consent - Written informed consent Inclusion criteria Controls: - Men and women - Capacity to consent - Written informed consent Group 1: age-matched, no neurological diseases with motor impairments, no autoimmunological diseases, no depression. Group 2: age-matched, other neuroimmunological diseases (e.g. multiple sclerosis, immune neuropathies)

Exclusion criteria

Exclusion criteria: General Exclusion Criteria: - Lack of communication skills - Alcohol or drug abuse (current)

Design outcomes

Primary

Measure	Time frame
Identification of risk factors as well as predictive biomarkers (immune markers, gene markers) in the early course of the disease (<12 months after first symptom) for progression (pure ocular, generalized or myasthenic crisis within 36 months). The planned study is a mixed prospective and retrospective observational study. Many parameters (antibody status, imaging of the thymus) are part of routine clinical diagnostics for MG patients. A special clinical examination (Q-motor), which allows quantification of motor functions by means of instrumental diagnostics, is used. The aim of this Q-motor examination is to compare its results with the results of the current diagnostic standard, the Besinger Score. In addition, it is a goal to use a very sensitive method to determine to what extent patients who are clinically assessed as having ocular progression do not have signs of generalization that are difficult to recognize.	—

Measure

Time frame

Identification of risk factors as well as predictive biomarkers (immune markers, gene markers) in the early course of the disease (<12 months after first symptom) for progression (pure ocular, generalized or myasthenic crisis within 36 months). The planned study is a mixed prospective and retrospective observational study. Many parameters (antibody status, imaging of the thymus) are part of routine clinical diagnostics for MG patients. A special clinical examination (Q-motor), which allows quantification of motor functions by means of instrumental diagnostics, is used. The aim of this Q-motor examination is to compare its results with the results of the current diagnostic standard, the Besinger Score. In addition, it is a goal to use a very sensitive method to determine to what extent patients who are clinically assessed as having ocular progression do not have signs of generalization that are difficult to recognize.

—

Secondary

Measure	Time frame
Identification of markers for response to specific therapies and for long-term disease progression, as well as for specific MG-specific findings through the systematic collection and analysis of the parameters described above.	—

Countries

Germany

Contacts

Public ContactAndreas Meisel

Klinik für NeurologieNeuroCure Clinical Research Center (NCRC)Charité Universitätsmedizin BerlinCharité Campus Mitte

andreas.meisel@charite.de+49 30 450 560026

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026